AI Defense Stock VisionWave Holdings (Nasdaq: $VWAV) Reports Closing of Its First Acquisition: Solar Drone Ltd; @VWAVInc

 

 

AI Defense Stock VisionWave Holdings (Nasdaq: $VWAV) Reports Closing of Its First Acquisition: Solar Drone Ltd; @VWAVInc

 

First Acquisition Since July 2025 de-SPAC; Company Expands Into Autonomous Robotics, Defense, and Energy Automation

 

 

 

  

DEC 4, 2025 Investorideas.com, a  top 100 rated investment site for retail Investors following  AI and defense stocks, reports  on  breaking news for  VisionWave Holdings, Inc ( Nasdaq: VWAV) , VisionWave Holdings, Inc. (Nasdaq: VWAV) today announced that it has entered into a definitive Share Purchase Agreement to acquire 100% of Solar Drone Ltd. , an autonomous robotics company and wholly owned subsidiary of BladeRanger Ltd. (TASE: BLRN).

 

This transaction marks the Company’s first acquisition since completing its de-SPAC in July 2025, and VisionWave emphasized that it continues to pursue additional acquisitions as part of its long-term strategic expansion; however, there can be no assurance that any additional acquisitions will be entered into or completed.

 

Paid News Dissemination on behalf of VWAV 

Read this news, featuring VWAV in full at https://www.investorideas.com/CO/VWAV/news/2025/12041-visionwave-holdings-acquires-solar-drone-autonomous-robotics-expansion.asp

 

Strategic Expansion Into Defense, Security & Industrial Robotics

Upon closing, Solar Drone’s platform is expected to create near-term synergies across VisionWave’s multi-domain ecosystem:

 

Defense & Security

Solar Drone’s platform could position VisionWave to provide autonomous mission capabilities in high-risk or GPS-denied environments, seamless integration with VisionWave’s RF-imaging, AI perception, and autonomous navigation architecture, and broad applications in border protection, perimeter defense, base security, and tactical reconnaissance.

 

Industrial Automation & Energy Infrastructure

The acquisition could also expand VisionWave into the high-demand solar operations and maintenance (O&M) robotics market by integrating Solar Drone’s proven AI-driven autonomous cleaning and inspection technology, delivering efficient, fully automated maintenance for large solar fields and a highly scalable solution for global renewable-energy assets. This opportunity is supported by a significant installed base of over 165 GW in the U.S. across more than 70,000 utility-scale sites (with the broader market projected to reach $36–40 billion annually by 2030; U.S. EIA / SEIA/Wood Mackenzie) and more than 260 GW in Europe growing by ~50 GW per year, driving an existing O&M segment of €6–8 billion annually (SolarPower Europe / IEA PVPS).

 

Investor Takeaway

The solar O&M market is sizable, and the Company believes Solar Drone’s technology is well-positioned to compete in this segment.

 

Europe First: Negotiations Underway with Drone Operator

VisionWave is engaged in ongoing commercial discussions with potential customers in Europe and elsewhere. The Company believes that, assuming the acquisition closes and integration proceeds as planned, 2026 could be a revenue-generating year for the solar O&M segment; however, no assurances can be given regarding the timing or amount of any such revenue.

 

Transaction Overview (as disclosed in Form 8-K):

 

In connection with the acquisition of Solar Drone, the Company will issue BladeRanger Ltd.:

 

·         1,800,000 VWAV shares of common stock

·         Pre-Funded Warrants may be issued in the event the VWAP upon the resale registration statement being declared effective is under $12.00, ensuring $21.6 million total consideration (subject to the terms and conditions set forth in the Share Purchase Agreement)

Closing is expected on or about December 10, 2025, subject to standard conditions.  The acquisition remains subject to the satisfaction or waiver of customary closing conditions, and there can be no assurance that the transaction will close on the anticipated timeline or at all.

 

Douglas Davis, Executive Chairman of VisionWave, commented:

 

“This acquisition is expected to be transformative for VisionWave. Solar Drone is expected to support our defense and autonomous robotics strategy. We continue to also evaluate additional strategic opportunities.”

 

For more information, please refer to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission.

 

About Solar Drone Ltd.

Solar Drone develops advanced autonomous robotic systems for large-scale industrial and renewable-energy applications, with AI-driven navigation and mission automation.

 

 

About VisionWave Holdings, Inc. (Nasdaq: VWAV)

VisionWave develops advanced multi-domain technologies integrating RF imaging, autonomous robotics, AI-powered sensing, and mission-critical automation for defense, energy, and industrial applications.

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the expected timing and completion of the proposed acquisition, anticipated synergies and benefits, future revenue potential, and additional acquisition opportunities. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, including the failure to satisfy closing conditions, integration challenges, market conditions, regulatory developments, and other factors described in the Company’s SEC filings. The Company undertakes no obligation to update any forward-looking statements.

 

Investor Contact:

investors@vwav.inc 

Website: https://www.vwav.inc

 

VisionWave is a Featured Defense stock on Investorideas.com

Research more defense stocks at Investorideas stock directory

https://www.investorideas.com/Companies/HomelandDefense/stock_list.asp

 

Disclaimer/Disclosure: VisionWave Holdings, Inc. is  a paid for featured defense company on Investorideas.com. Investorideas is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions.
More disclaimer info:  Learn more about publishing your news release and our other news services on the Investorideas.com newswire 

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: 

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all.

 

Advertising agencies -Learn more about digital advertising and guest posts at Investorideas

 

Follow & Contact

Follow us on X: @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

 

 

AI Telecom Stock IQSTEL Inc. (Nasdaq: $IQST) Confirms $500,000 Shareholder Dividend to Be Paid on December 30th, @IQstel

AI Telecom Stock IQSTEL Inc. (Nasdaq: $IQST) Confirms $500,000 Shareholder Dividend to Be Paid on December 30^th, @IQstel

 

Free-Trading IQST Common Shares as Part of Its Long-Term Shareholder Value Strategy

 

 

Transfer Agent to Match DTC Positions With Broker Records to Ensure Accurate and Timely Distribution of Dividend Shares

 

  

(Investorideas.com Newswire) Breaking Telecom and AI stock news from Investorideas.com, a top 100 rated investment site for retail Investors. IQSTEL Inc. (NASDAQ: IQST) confirmed its plan to distribute a $500,000 dividend on December 30^th, 2025, payable in free-trading IQST common shares. This dividend is a key milestone as the company enters a new phase of long-term value creation and advances its broader strategy to evolve into a $1 billion revenue corporation.

 

This dividend distribution stems from the strategic agreement executed with Cycurion CYCU, which strengthened the long-term cooperation and development roadmap shared by both companies.

 

Paid news dissemination for IQST

Read this news in full at: https://www.investorideas.com/news/2025/technology/12031-iqstel-announces-500k-shareholder-dividend-december-2025.asp

 

The news about the original agreement can be reviewed here:

https://finance.yahoo.com/news/iqst-iqstel-cycurion-cycu-execute-123000434.htmlç

 

Dividend Structure and Calculation

The $500,000 dividend will be calculated using the August 29, 2025 closing price of $6.62, resulting in:

   •      Total dividend shares: 75,529 free-trading IQST common shares

   •      Record Date: December 15^th, 2025

   •      Payment / Distribution Date: December 30^th, 2025

   •      Distributed by IQSTEL Transfer Agent: V-Stock Transfer

 

Only shareholders holding IQST common shares on the Record Date of December 15^th, 2025 will be eligible to receive this dividend.

 

With 4,374,822 shares outstanding, the resulting distribution ratio is 0.0173.

Shareholders can determine their allocation by multiplying their share count by 0.0173.

 

All allocations will be rounded down, and no cash in lieu will be issued.

 

Operational Note for Shareholders

To ensure a smooth and accurate distribution, IQSTEL has instructed its transfer agent to match DTC positions with broker-reported share balances.

 

CEO Comment

IQSTEL CEO Leandro Iglesias stated:

 

“We are proud of who we are as a company and what we have achieved together. IQSTEL has fulfilled every promise we made to our shareholders—not only delivering strong operating results, but also tangible, measurable shareholder value. Now, as we enter a new stage with a clear path toward becoming a $1 billion revenue corporation, our commitment to our shareholders is stronger than ever. Beginning this year, IQSTEL intends to issue dividends annually, tied directly to our performance and growth. This $500,000 dividend is a testament to our vision, our execution, and our unwavering dedication to rewarding those who believe in our mission.”

 

About IQSTEL Inc.

IQSTEL Inc. (NASDAQ: IQST) is a Global Connectivity, AI, and Digital Corporation providing advanced solutions across Telecom, High-Tech Telecom Services, Fintech, AI-Powered Telecom Platforms, and Cybersecurity. With operations in 21 countries and a team of 100 employees, IQSTEL serves a broad global customer base with high-value, high-margin services. Backed by a strong and scalable business platform, the company is forecasting $340 million in revenue for FY-2025, reinforcing its trajectory toward becoming a $1 billion tech-driven enterprise by 2027.

 

Safe Harbor Statement: Statements in this news release may be "forward-looking statements". Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. Words such as "anticipate," "believe," "estimate," "expect," "intend", "could" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully market our products and services; our continued ability to pay operating costs and ability to meet demand for our products and services; the amount and nature of competition from other telecom products and services; the effects of changes in the cybersecurity and telecom markets; our ability to successfully develop new products and services; our ability to complete complementary acquisitions and dispositions that benefit our company; our success establishing and maintaining collaborative, strategic alliance agreements with our industry partners; our ability to comply with applicable regulations; our ability to secure capital when needed; and the other risks and uncertainties described in our prior filings with the Securities and Exchange Commission.

 

These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and IQSTEL Inc. undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.

 

For more information, please visit www.IQSTEL.com.

 

Official Investors Landing Page: www.landingpage.iqstel.com

 

Investor Relations Contact:

IQSTEL Inc.

300 Aragon Avenue, Suite 375, Coral Gables, FL 33134

Email: investors@IQSTEL.com

 

Watch Investorideas recent YouTube short featuring IQST

https://youtube.com/shorts/7SrgsItDjys?feature=share

 

Research more tech stocks with Investorideas.com free stock directory

https://www.investorideas.com/TSS/stock_list.asp

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all.

Disclaimer/Disclosure: This article featuring Nasdaq:IQST is paid for content and news dissemination. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

More disclaime: https://www.investorideas.com/About/Disclaimer.asp

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

AI Defense Stock VisionWave Holdings (Nasdaq: $VWAV) Unveils Argus, A Space Enabled AI Counter Drone System; @VWAVInc

 

 

 

AI Defense Stock VisionWave Holdings (Nasdaq: $VWAV) Unveils Argus, A Space Enabled AI Counter Drone System; @VWAVInc

 

New A Space Enabled AI Counter Drone System to be Developed in Partnership with BladeRanger

 

 

DEC 2, 2025 Investorideas.com, a  top 100 rated investment site for retail Investors following  AI and defense stocks, reports  on news for  VisionWave Holdings, Inc ( Nasdaq: VWAV) , VisionWave Technologies Inc., a wholly owned subsidiary of VisionWave Holdings, Inc today announced that it has begun R&D on Argus, a space-enabled, AI-driven counter-drone (C-UAS) system created in collaboration with BladeRanger to defend against modern unmanned aircraft threats. Argus is designed to detect, classify, track, and defeat hostile unmanned aircraft across wide operational areas.

 

Argus takes its name from the many-eyed guardian in Greek mythology, symbolizing persistent and continuous watchfulness. It is designed as a global counter-drone kill chain that operates from space and uses high-frequency (HF) communications to coordinate defense assets across wide areas. The system combines space-based imaging, advanced object-recognition AI, resilient HF connectivity, and a layered mix of interceptors and effectors. VisionWave has completed the system architecture and plans to file a patent application in the coming weeks covering its core technical innovations (which application has not yet been filed and for which no assurance of allowance can be given).

 

Paid News Dissemination on behalf of VWAV 

Read this news, featuring VWAV in full at https://www.investorideas.com/CO/VWAV/news/2025/12021-visionwave-vwav-ai-space-enabled-argus-counter-drone-system-launch.asp

 

“Modern conflicts have shown that small drones and loitering munitions can redefine the battlefield with little warning,” said Doug Davis, VisionWave Chairman. “Argus is intended to be designed to designed to provide nations with a theater-scale shield that can detect hostile drones from space, classify them instantly, and coordinate a precise response in real time, even in highly contested environments.”

 

A space-enabled, AI-driven kill chain

Argus is intended to be designed to function as a persistent, multi-layered defense system. In the space segment, satellites equipped with EO/IR and optional SAR/RF payloads are expected to provide continuous monitoring of borders, critical infrastructure, ports, and urban areas. These sensors are intended to detect and track the full spectrum of small and tactical drones at operationally meaningful ranges, creating an early warning layer over wide areas.

 

On top of this sensor layer, Argus is intended to apply AI-driven, object-recognition technology that identifies structural features such as rotors, arms, fuselage, and wings. Using multi-view imagery, it reconstructs a virtual 3D model and fuses it with behavioral cues such as flight profile and loitering patterns to classify drone type, evaluate potential payloads, and generate a real-time threat score.

 

For resilient connectivity, Argus is intended to use an AI-controlled HF backbone that is expected to maintain beyond line-of-sight communications between satellites, ground stations, interceptor sites, and remote sensors, even when SATCOM, cellular, or microwave links are jammed or disabled. The HF system continuously models ionospheric conditions and selects frequencies, paths, and antenna configurations to preserve reliable links.

 

A dedicated security layer uses asynchronous encryption to harden GPS and command-and-control (C2) links used to send instructions to drones, sensors, and interceptors, and to receive status and telemetry from them. A proprietary asynchronous key exchange is intended to protect HF command and control channels and GPS correction messages, with the goal of making Argus highly resistant to jamming, spoofing, and man in the middle attacks. This cryptographic layer is designed to protect both navigation integrity and command authority in contested environments.

 

At the engagement layer, Argus is intended to use layered interceptors and effectors to coordinate a wide range of responses. These include interceptor drones, ground-based rapid-fire systems, RF jammers, deceptive navigation injectors, and optional lasers or high-power microwave assets. Together, they support both soft-kill and hard-kill options, allowing the system to tailor its response to each specific threat scenario.

 

Targeting major C-UAS defense market share

VisionWave is aiming for the global defense C-UAS market. The company believes the Argus architecture may position it uniquely in the rapidly expanding counter-drone domain. By combining space-based early warning, small-object recognition derived from facial-recognition heritage, all-weather HF connectivity, and strong encryption, VisionWave hopes  to offer a system that can scale from national borders and strategic infrastructure to ports, bases, and high-value events.

 

“Most C-UAS solutions today are local with one radar, one camera, one gun protecting a single base or airport,” said Shmulik Yannay, BladeRanger CEO. “Argus is designed from day one as a wide-area, multi-domain system. Our objective is to capture a major share of the global defense C-UAS market by offering a solution that is space-enabled, resilient, and ready for near-peer electronic warfare.”

 

Argus will be built on existing VisionWave technologies that have already been developed and validated in other programs. These include advanced encryption for HF communications and GPS augmentation, patented pattern-recognition technology, and an AI-driven HF network for non-line-of-sight connectivity. Leveraging these assets is expected to shorten the Argus R&D timeline as the company advances from architecture and simulation into prototyping and field demonstrations; however, no assurance can be given that such timeline will be met or that the system will perform as anticipated.

 

About VisionWave Holdings, Inc. (VWAV)

VisionWave develops advanced airborne, RF-sensing, and AI-powered technologies serving the defense, homeland-security, and critical-infrastructure sectors. VisionWave’s mission is to enhance national-level safety, intelligence, and operational resilience through next-generation sensing and autonomous platforms.

 

About BladeRanger

BladeRanger develops industrial-grade drone-based solutions for grid maintenance, fire prevention, and optimization. The company’s proprietary payloads, AI analytics, and autonomous workflows are engineered to deliver safer, cleaner, and more efficient operations across large-scale energy and infrastructure environments.   VisionWave has entered into a binding Letter of Intent to acquire its subsidiary - the transaction has not closed yet and remains subject to numerous conditions, and there can be no assurance that the transaction will be completed on the contemplated timetable or at all.

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including without limitation statements regarding the proposed acquisition of Solar Drone Ltd., a subsidiary of BladeRanger, potential integration of technologies, the development, performance, capabilities, and commercialization of Argus, and any future business or commercial opportunities. In particular, there is no assurance the proposed acquisition will be completed on the contemplated timetable or at all and no assurance that Argus will be successfully developed, achieve the anticipated performance characteristics, or result in any commercial opportunities. Words such as “will,” “expects,” “believes,” “potential,” “anticipated,” “intends,” “plans,” “designed,” and similar expressions identify forward-looking statements. Actual outcomes may differ materially. Forward-looking statements are based on current expectations and are subject to risks and uncertainties described in VisionWave’s filings with the U.S. Securities and Exchange Commission. VisionWave undertakes no obligation to update these statements except as required by law. See VisionWave’s most recent Form 10-K and 10-Q for a fuller list of risk factors. The Company undertakes no obligation to update these statements.

 

Investor Contact:

investors@vwav.inc 
Website: https://www.vwav.inc

 

VisionWave is a Featured Defense stock on Investorideas.com

Research more defense stocks at Investorideas stock directory

https://www.investorideas.com/Companies/HomelandDefense/stock_list.asp

 

Disclaimer/Disclosure: VisionWave Holdings, Inc. is  a paid for featured defense company on Investorideas.com. Investorideas is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions.
More disclaimer info:  Learn more about publishing your news release and our other news services on the Investorideas.com newswire 

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: 

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all.

 

Advertising agencies -Learn more about digital advertising and guest posts at Investorideas

 

Follow & Contact

Follow us on X: @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

 

Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Announces Publication of Hemopurifie Preclinical Data

 

Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Announces Publication of Hemopurifie Preclinical Data

 

Data Showing That the GNA Affinity Resin in the Hemopurifier® Binds to Extracellular Vesicles in Long COVID patient samples and Decreases Inflammatory microRNAs

 

Results Support the Further Investigation of the Hemopurifier in Long COVID

 

 

 

December 2, 2025  – (Investorideas.com Newswire) Reports Breaking Medical Tech Stock news -  Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, announced today the 20 November 2025 publicationof a pre-clinical study entitled “Increased mannosylation of extracellular vesicles in Long COVID plasma provides a potential therapeutic target for Galanthus nivalis agglutinin (GNA) affinity resin” in the pre-print online archive bioRxiv. This paper has simultaneously been submitted for consideration to a peer-reviewed journal.  

https://www.biorxiv.org/cgi/content/short/2025.11.21.689519v1

 

Long COVID refers to persistent symptoms following acute SARs-CoV-2 infection (COVID-19). These symptoms - including fatigue, post-exertional malaise, shortness of breath, chest pain, and cognitive difficulties such as “brain fog” - may last for weeks or months after the initial illness. Long COVID is estimated to affect between 44 and 48 million people in the United States alone with a projected economic burden of $2 billion for those with symptoms lasting a year. Despite over $1 billion allocated to Long COVID research funding, no treatment has proven effective.

 

 

Extracellular vesicles (EVs), nanoparticles 50-500nm in diameter, released from all cell types and involved in cell-to-cell communication, have been implicated in the pathogenesis of Long COVID.  EVs have been found to contain viral particles and other cargo including microRNA which are tiny molecules that regulate the amount of proteins made and have been associated with abnormal blood clotting and inflammation.

 

Aethlon Medical’s Hemopurifier® is an investigational extracorporeal device designed to bind and remove harmful EVs from the blood through a combination of plasma separation, size exclusion and binding to a proprietary affinity resin containing the plant lectin Galanthus nivalis agglutinin (GNA), previously found to bind to the sugar mannose.

 

The Hemopurifier has previously been shown to remove EVs and decrease microRNAs in a patient with severe acute COVID-19 infection. Aethlon Medical collaborated with the University of California San Francisco Medical Center Long COVID clinic to evaluate plasma samples from participants with Long COVID and control participants who had recovered from COVID-19. Large (100−500 nm) and small (40−200 nm) EVs were isolated from plasma samples to determine ability to bind to GNA (mannose positive) or be removed by the GNA affinity resin, respectively. Plasma of those with Long COVID contained elevated levels of both large and small EVs.  Mannose-positive large EVs were significantly increased in Long COVID patient samples comparison to recovered controls. Removal of small EVs by the GNA affinity resin correlated with mannose positive large EVs indicating the same glycan target for removal by the Hemopurifier was present in both populations.  NanoString analyses identified seven EV associated miRNAs significantly depleted by GNA affinity resin treatment of plasma. The use of Pathway activity interference software indicated that removal of these microRNAs may be associated with downregulation of inflammatory pathways, including JAK-STAT, and upregulation of tissue repair pathways.

 

Paid News Dissemination of behalf of AEMD

Read this news, featuring AEMD in full at https://www.investorideas.com/CO/AEMD/news/2025/12021-aethlon-medical-aemd-hemopurifier-long-covid-preclinical-data-2025.asp

“The data from this ex vivo study is exciting because it demonstrated for the first time that the GNA affinity resin in our device removes extracellular vesicles in Long COVID patient samples and removes microRNAs associated with the JAK-STAT pathway which is a therapeutic target in current Long COVID clinical trials. We plan to further this work by examining if removal of EVs decreases SARSs -CoV-2 viral particles as viral persistence is thought to be an additional important pathogenic mechanism in Long COVD” said Steven P. LaRosa, MD, Chief Medical Officer at Aethlon Medical and senior author on the paper.  “While Oncology is our lead clinical indication, this pre-clinical provides additional evidence that EV removal is a target beyond cancer.  We see the potential of the Hemopurifier as “a pipeline within a single device” “said James Frakes, Chief Executive Officer at Aethlon.

 

About Aethlon and the Hemopurifier®

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful EVs from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where EVs may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which EVs have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

 

Additional information can be found at www.AethlonMedical.com.

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to raise additional capital and to successfully complete development of the Hemopurifier; the Company’s ability to successfully demonstrate the utility of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the ability of the Hemopurifier to continue to show removal of platelet -derived EVs at a timepoint equivalent to a 4-hour HP treatment; the manuscript described in this release being under review and may be rejected for publication, require substantial revision, or be interpreted differently by the scientific community; the Company’s ability to achieve and realize the anticipated benefits from potential milestones; the Company’s ability to submit applications to and obtain approval from the additional Ethics Committees in Australia and India, including on the timing expected by the Company; the Company’s ability to initiate and continue its planned oncology clinical trials in Australia and India, including on the timing expected by the Company; the Company’s ability to manage and successfully complete its clinical trials, if initiated; the Company’s ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials, and other potential risks. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2025, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. The preclinical findings described herein are preliminary in nature, have not been peer-reviewed, and may not be replicated in subsequent studies or clinical trials.

 

Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com

 

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com   
917-513-5303

 

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

 

More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/

 

Get News Alerts on Aethlon Medical

 

Disclaimer/Disclosure: Athelon Medical, Inc. (AEMD) is a paid featured medical tech stock on Investor ideas More disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. More disclosure: Contact management and IR of each company directly regarding specific questions.

 

Get more biotech and medical tech news, articles, podcasts and stock directories

 

 

 

 

 

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp